gevokizumab

Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M
Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M
Endpoints
Novartis
Xoma
M&A
gevokizumab
cardiovascular disease
Flag link:
Decimated by clinical failure, Xoma turns to plan B
Decimated by clinical failure, Xoma turns to plan B
Fierce Biotech
Xoma
clinical trials
gevokizumab
XOMA 358
endocrine disorders
Flag link:
Already with $1 billion in losses, Xoma plummets with late-stage drug failure
Already with $1 billion in losses, Xoma plummets with late-stage drug failure
Bizjournals.com
Xoma
gevokizumab
Behcet's uveitis
Flag link:
Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head
Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head
TheStreet.com
Xoma
gevokizumab
Flag link:
3 Biotech Stocks With Upcoming Data That Could Be Huge
3 Biotech Stocks With Upcoming Data That Could Be Huge
24/7 Wall St
Aerie Pharma
Ocular Therapeutix
Xoma
gevokizumab
Rhopressa
OTX-TP
Flag link:
This Week in Biotech: Put It in Print
This Week in Biotech: Put It in Print
Motley Fool
Endo
Aveed
Rigel Pharmaceuticals
R118
Sangamo BioSciences
SB-728-T
NewLink Genetics
Xoma
gevokizumab
Flag link:
Xoma to stop testing drug as arthritis treatment
Xoma to stop testing drug as arthritis treatment
Yahoo/Reuters
Xoma
gevokizumab
osteoarthritis
Flag link:
XOMA completes enrollment in Phase 2 POC Gevokizumab trial
XOMA completes enrollment in Phase 2 POC Gevokizumab trial
Yahoo/Fly on the Wall
Xoma
gevokizumab
osteoarthritis
Flag link:
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
TheStreet.com
Zerenex
Xoma
Vical
Takeda
sovaprevir
Soluble Ferric Pyrophosphate
Rockwell Medical
Orexigen
MM-398
Merrimack Pharmaceuticals
MannKind
Keryx
GTx
GSK
gevokizumab
enobosarm
Coronado Biosciences
Contrave
CNDO-201
clinical trials
ChemoCentryx
CCX140
Biodel
BIOD-123
Amigal
Amicus Therapeutics
Alnylam
ALN-TTR02
Allovectin
Afrezza
Achillion
ACH-3102
Flag link:
XOMA selects non-infectious anterior scleritis as next indication in POC program
XOMA selects non-infectious anterior scleritis as next indication in POC program
The Fly on the Wall
Xoma
non-infectious anterior scleritis
gevokizumab
Flag link:
XOMA Receives Orphan Drug Designation From U.S. Food & Drug Administration for Gevokizumab
XOMA Receives Orphan Drug Designation From U.S. Food & Drug Administration for Gevokizumab
Yahoo
Xoma
FDA
orphan drugs
gevokizumab
uveitis
Flag link:
XOMA Enrolls for Gevokizumab Trials
XOMA Enrolls for Gevokizumab Trials
Yahoo/Zacks
Xoma
gevokizumab
uveitis
Flag link: